

Journal Pre-proof



How Should the Rehabilitation Community Prepare for 2019-nCoV?

Gerald Choon-Huat Koh, PhD, Helen Hoenig, MD

PII: S0003-9993(20)30153-2

DOI: <https://doi.org/10.1016/j.apmr.2020.03.003>

Reference: YAPMR 57796

To appear in: *ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION*

Received Date: 10 March 2020

Revised Date: 10 March 2020

Accepted Date: 11 March 2020

Please cite this article as: Koh GC-H, Hoenig H, How Should the Rehabilitation Community Prepare for 2019-nCoV?, *ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION* (2020), doi: <https://doi.org/10.1016/j.apmr.2020.03.003>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc. on behalf of the American Congress of Rehabilitation Medicine

Running Head: How Should the Rehabilitation Community Prepare for 2019-nCoV?

How Should the Rehabilitation Community Prepare for 2019-nCoV?

Gerald Choon-Huat KOH^{1*}, PhD; Helen HOENIG², MD

*Corresponding Author

¹Saw Swee Hock School of Public Health, National University of Singapore, Singapore

²Physical Medicine and Rehabilitation Service, Durham VA Medical Centre, USA

Funding: Nil

Conflict of Interest: None

***Corresponding author**

Dr Gerald CH Koh

Saw Swee Hock School of Public Health

National University of Singapore

12 Science Drive 2

#10-01

Singapore 117549

Tel (65) 6516 4979

Fax (65) 6779 1489

Email: gerald_koh@nuhs.edu.sg

SPECIAL COMMUNICATION**How Should the Rehabilitation Community Prepare for 2019-NCOV?****Abbreviations Used:**

- 2019-nCoV/COVID-19: Novel coronavirus (2019)
- SARS-CoV: Severe Acute Respiratory Syndrome
- MERS-CoV: Middle East Respiratory Syndrome
- CFR: Case fatality rate
- WHO: World Health Organization
- RT-PCR: Reverse transcriptase–polymerase chain reaction
- RNA: Ribonucleic acid
- PPE: Personal protective equipment
- HCW: Healthcare worker

Abstract

With the 2019-nCoV pandemic spreading quickly in USA and the world, it is urgent that the rehabilitation community quickly understands the epidemiology of the virus and what we can and must do to face this microbial adversary at the early stages of this likely long global pandemic. The 2019-nCoV is a novel virus so the majority of world's population does not have prior immunity to it. It is more infectious and fatal than seasonal influenza, and definitive treatment and a vaccine are months away. Our arsenal against it are currently mainly social distancing and infection control measures.

Main Text

In late December 2019, a novel coronavirus 2019-nCoV emerged from Wuhan, Hubei Province, China,¹ and by early January 2020, Singapore became the country with second highest number of cases.² On 30 January 2020, Centers for Disease Control and Prevention (CDC) confirmed the first person-to-person transmission of 2019-nCoV in the United States.³ Although 2019-nCoV is phylogenetically similar to Severe Acute Respiratory Syndrome (SARS-CoV) in 2003 and Middle East Respiratory Syndrome (MERS-CoV) in 2012, its disease characteristics such as reproduction ratio (R_0), case fatality rate (CFR) and symptomatology more resemble the seasonal influenza virus (**Table 1**). Nevertheless, 2019-nCoV appears to be as, if not more, contagious and have 2-times higher CFR than seasonal influenza.

Epidemiology of 2019-nCoV

The World Health Organization (WHO) - China Joint Mission COVID-19 (the WHO name for 2019-nCoV) where 25 local and international experts investigated the outbreak in China, found that the main mode of transmission was contact and droplet (not aerosol).⁴ It also found that most of the 2,000+ infected hospital workers was either infected at home or from patient contact in the early phase of the outbreak in Wuhan when hospital safeguards were not raised yet. Asymptomatic transmission was rare. 80% of laboratory confirmed patients had mild to moderate disease, 13.8% had severe disease (dyspnea, tachypnea, oxygen desaturation

41 or chest-X-ray infiltrates >50% of the lung field within 24-48 hours) and 6.1% were critically ill (respiratory
42 failure, septic shock, and/or multiple organ dysfunction/failure). 20% of 2019-nCoV patients needed
43 supplemental oxygen, of which a quarter needed artificial respiration. Mortality increases with age, with the
44 highest mortality among people over 80 years of age (CFR 21.9%). Compared to patients had no comorbid
45 conditions who had a CFR of 1.4%, the CFR for patients with cardiovascular disease was 13.2%, 9.2% for
46 diabetes, 8.4% for hypertension, 8.0% for chronic respiratory disease, and 7.6% for cancer. Disease in
47 children appears to be relatively rare and mild.

48 49 *Public Health Measures to Contain 2019-nCoV*

50 The escalating outbreak in Hubei was reversed through China's use of aggressive public health measures
51 such as proactive surveillance to detect cases immediately, rapid diagnosis and immediate case isolation,
52 rigorous tracking and quarantine of close contacts, and an exceptionally high degree of population
53 understanding and acceptance of these measures. Is the global community ready, in mind-set and resources,
54 to implement such measures? For countries with imported cases and/or early outbreaks of 2019-nCoV like the
55 US, WHO recommends the immediate following actions detailed in **Table 2**.

56 57 **Diagnosis of 2019-nCoV**

58 There are three main ways to detect 2019-nCoV in naso-oro-pharyngeal, broncho-alveolar, blood and fecal
59 samples, each with its distinct diagnostic value:

- 60 • Active virus shedding: Reverse transcriptase–polymerase chain reaction (RT-PCR) of 2019-nCoV single-
61 stranded RNA. Turnaround for testing can be as short as 3-6 hours but RT-PCR requires specialised
62 machines, test kits and expertise so they are not easily available and accessible; thus, transportation time
63 needs to be factored in.⁵
- 64 • With presence of symptoms and signs of pneumonia in high 2019-nCoV-load hospital settings and where
65 sampling is too high risk [(e.g. shortage of personal protective equipment (PPE))]: Chest computed
66 tomography with its characteristic features of ground glass opacities and consolidation may be useful.⁶
- 67 • Past infection: Serological testing now available but false-positive and false-negative rates are still
68 uncertain.⁷

69 70 **Patient Management of 2019-nCoV**

71 The mainstay of treatment of 2019-nCoV is symptomatic until the infected self-recovers. For the sub-group of
72 patients who develop severe disease, besides intensive care, studies are underway to explore the use of anti-
73 virals, anti-inflammatories and monoclonal antibodies, especially in those who develop cytokine storm.⁸
74 Vaccines are also being developed but experts estimate that it will take 6 months before scientists know
75 whether any of the vaccines in development will help against 2019-nCoV and at least a year before one will be
76 ready for human use.

77 78 79 **Rehabilitation During 2019-nCoV Outbreak**

80 81 General Advice

82

83 For both staff and patients, the following precautions should be adopted: personal hygiene; CDC's
84 handwashing advice⁹; staying home if you have flu symptoms; if unwell, seek medical help and wear a mask
85 when venturing outside. Misinformation and misconceptions can trigger panic and irrational behaviour so
86 everyone should stay up-to-date on the rapidly evolving 2019-nCoV situation from reliable information sources
87 like CDC (<https://www.cdc.gov/media/rss-govd.html>) & WHO
88 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>) who can send
89 persons updates automatically. Everyone can expect more social distancing measures including business
90 continuity plans such a split-teams, restricted movement and work-from-home arrangements, periodic school
91 closures and remote learning, travel restrictions, greater use of video-conferencing, e-commerce platforms,
92 tele-medicine, and fewer large social events and gatherings.

93

94 Patient Challenges

95

96 *Deconditioning*

97 For our patients undergoing rehabilitation who need to be quarantined (e.g. from contact with a positive case)
98 or when they themselves become ill with 2019-nCoV, deconditioning and how to provide rehabilitation while
99 protecting healthcare staff are major concerns. Practical advice would include continuation of home exercises
100 last prescribed, and continued attendance at rehabilitation centres if well but with stepped-up infection control
101 measures such as patient screening for fever and flu symptoms at the entrance. Systematic reviews on tele-
102 rehabilitation interventions after stroke have demonstrated either better or equal salutary effects on motor,
103 higher cortical, and mood disorders compared with conventional face-to-face therapy.¹⁰ However, studies on
104 the effectiveness of tele-rehabilitation for non-stroke conditions are still lacking. Nevertheless, during
105 situations like outbreaks, tele-rehabilitation has the additional advantage of continuing rehabilitation
106 supervision remotely without risk of virus exposure.

107

108 *Infection Risk*

109 Diabetes is an immunocompromising disease that increases the risk of severe 2019-nCoV infection and
110 mortality. Diabetes is also a risk factor for common conditions that require rehabilitation like cardiovascular
111 disease and stroke which themselves increase the mortality risk. Other common conditions needing
112 rehabilitation like chronic respiratory disease and cancer are also associated with higher risk of mortality from
113 2019-nCoV. Hence, our rehabilitation patients are at higher risk of severe and fatal 2019-nCoV infections. For
114 those who are capable of performing rehabilitation at home with guidance from tele-rehabilitation, this should
115 be their first option. For the rest who need centre-based or inpatient rehabilitation, we recommend fever and
116 flu symptom monitoring to separate the well from the unwell, and strict infection control measures including
117 handwashing between patients to reduce virus transmission. Patients who are symptomatic should be
118 separated from the well, quarantined and tested for 2019-nCoV, and isolated and treated if positive. Hospital
119 management should designate and prepare isolation rooms with adequate PPE and trained staff.

120

121 Staff Challenges

122

123 *Infection control*

124 When local transmission is established, healthcare workers (HCWs) on the frontline should wear personal
125 protective equipment (PPE – e.g. masks, gloves and gowns, etc). The level of PPE protection should be
126 titrated against the risk of infection according to hospital protocols. Hospital management should procure
127 sufficient PPE supplies for staff for several months, taking into account surge need which depends on the
128 evolving epidemic curve for one's state or country. Staff should be re-trained on PPE donning and removal
129 procedures and mask re-fitting if masks available have never been fit-tested by staff.

130
131 Another concern pertains to the staff-patient-*environment* interface, particularly with regards to rehabilitation
132 equipment. Environmental persistence of coronaviruses varies with ambient temperature and humidity,
133 surface type and viral inoculum load. The coronavirus can persist on inanimate surfaces at typical room
134 temperatures and humidity for up to 9 days but inactivated efficiently by surface disinfection procedures with
135 62–71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite within 1 minute.¹¹ While evidence on
136 infection control specific to rehabilitation settings is sparse, limited data has shown persistence of bacterial
137 contaminants in rehabilitation equipment such as electrode sponges, water for hot pack units, topical lotions
138 and therapy ball pits.^{12,13,14,15,16} Hence, we should also pay attention to infection control for such surfaces, in
139 consultation with local infection control experts and with consideration of available disinfectants.

141 *Occupational Risks*

142 Wearing of PPE may be uncomfortable for HCWs, especially with N95 masks which requires greater effort to
143 breathe when worn. It may not be wise to deploy HCWs with chronic respiratory problems to hospital areas
144 that require high level of PPE protection which include N95 masks. Frequent handwashing and glove allergy
145 often trigger itchy and wet hand eczema and will affect staffs' ability to work. Emollients and steroid creams
146 should mitigate irritant and allergic eczema. Rehabilitation staff like speech and swallowing therapists and
147 chest physiotherapists are at increased risk because they are in close contact and exposed directly to
148 respiratory droplets from patients. Thus, they should wear high levels of PPE protection.

150 *Business Continuity Plans*

151 Business Continuity Plans are organizational strategies that allow the workforce to continue functioning if a
152 significant subset of the workforce needs to be quarantined or worse, falls ill. This usually involves
153 arrangements like split teams, restricted movement and work-from-home arrangements. With the exception of
154 clerical staff and tele-rehabilitation, it is impractical for rehabilitation HCWs to work from home as our
155 discipline is very hands-on. Hence, strategies like split teams and restricted movement are more relevant in
156 rehabilitation. Split teams is complete physical division of a workforce into (usually two) sub-teams with each
157 containing the necessary skill sets to continue most of its functions if one sub-team becomes unable to work.
158 Restricted movement is another strategy whereby the principle is every staff in a sub-team does not come in
159 physical contact with any staff from other sub-team(s) to minimise risk of cross-infection. Hospital
160 management should also review triage processes at entry points and workflows that separate high-risk from
161 low-risk areas and sub-teams. Other often forgotten issues are HCWs who are parents of young children. If
162 schools or day care centres close and both parents are working, HCWs may be forced to stay home to look
163 after them. HCWs may also be afraid to return home after work in fear to passing loved ones the virus if

164 infected and infectious during the asymptomatic phase. Hospital management should also explore alternative
 165 childcare and temporary rooming arrangements for staff.

166

167 *Communication with Staff*

168 Just as it is important for everyone to stay up-to-date about 2019-nCoV, it is especially important for hospital
 169 management to update staff regularly and in a timely manner about 2019-nCoV policies and situation which
 170 typically evolve day-to-day. Staff and their managers should ensure that communication channels are open
 171 and information is flowing bi-directionally. Staff should also carefully read management circulars and seek
 172 clarification if needed.

173

174 2019-nCoV is a novel virus so the majority of world's population does not have prior immunity to it. It is more
 175 infectious and fatal than seasonal influenza, and definitive treatment and a vaccine are months away. Our
 176 arsenal against it are currently mainly social distancing and infection control measures. We hope this paper
 177 that is targeted at the rehabilitation community outlines the epidemiology of the virus and what we as
 178 rehabilitation professionals can and must do to face this microbial adversary at the early stages of this likely
 179 long global pandemic.

180

181

182

References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Li M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JTK, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. doi: 10.1056/NEJMoa2001316.
2. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report 27. Downloaded from <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200216-sitrep-27-covid-19.pdf> on 17 Feb 2020.
3. CDC. CDC Confirms Person-to-Person Spread of New Coronavirus in the United States. Accessed <https://www.cdc.gov/media/releases/2020/p0130-coronavirus-spread.html> on 2 March 2020.
4. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Accessed <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf> on 3 Mar 2020.
5. CDC. Coronavirus Disease 2019 (COVID-19). Information for Laboratories. Interim Guidance for Laboratories. Downloaded from <https://www.cdc.gov/coronavirus/2019-nCoV/lab/index.html> on 11 Mar 2020.
6. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology* 2020. p.200642.
7. Centre for Health Security. John Hopkins Bloomberg School of Public Health. Serology testing for COVID-19. 28 Feb 2020. Downloaded from <http://www.centerforhealthsecurity.org/resources/COVID-19/200228-Serology-testing-COVID.pdf> on 11 March 2020.
8. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. *Lancet Infect Dis*. Published online on 27 Feb 2020 ahead of print. doi: [https://doi.org/10.1016/S1473-3099\(20\)30132-8](https://doi.org/10.1016/S1473-3099(20)30132-8).
9. CDC. When and How to Wash Your Hands. Accessed <https://www.cdc.gov/handwashing/when-how-handwashing.html> on 3 March 2020.
10. Sarfo FS, Ulasavets U, Opare-Sem OK, Ovbiagele B. Tele-Rehabilitation after Stroke: An Updated Systematic Review of the Literature. *J Stroke Cerebrovasc Dis* 2018;27:2306-2318.
11. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. *Journal of Hospital Infection* 2020;104(3):246-51. <https://doi.org/10.1016/j.jhin.2020.01.022>

12. Aljadi SH, Al-Shemmari M, Al-Ramzi J, Al-Abdullatif S, Hajeyah Z, Jamal L, Al-Bahar S. Bacterial contamination in physical therapy departments in the State of Kuwait. *Journal of Physical Therapy Science* 2017;29(6):1014-8. <https://doi.org/10.1589/jpts.29.1014>
13. Mobin M, de Moraes Borba C, de Moura Filho OF, de Melo Neto AQ, Valenti VE, Vanderlei LC, de Abreu LC. The presence of fungi on contact electrical stimulation electrodes and ultrasound transducers in physiotherapy clinics. *Physiotherapy* 2011;97(4):273-7. <https://doi.org/10.1016/j.physio.2010.11.010>
14. Lambert I, Tebbs SE, Hill D, Moss HA, Davies AJ, Elliott TS. Interferential therapy machines as possible vehicles for cross-infection. *Journal of Hospital Infection* 2000;44(1):59-64. <https://doi.org/10.1053/jhin.1999.0647>
15. Spratt Jr HG, Levine D, Bage J, Giles DK, Collier AG. Topical lotions utilized in outpatient rehabilitation clinics as a potential source of bacterial contamination. *Physiotherapy Theory and Practice* 2019;35(2):163-70. <https://doi.org/10.1080/09593985.2018.1441935>
16. Oesterle ME, Wright K, Fidler M, Johnson P, Bialonska D. Are ball pits located in physical therapy clinical settings a source of pathogenic microorganisms? *American Journal of Infection Control* 2019;47(4):456-8. <https://doi.org/10.1016/j.ajic.2018.09.031>

Table 1. Comparison of disease characteristics of SARS, MERS and season influenza with 2019-nCoV^{i,ii,iii}

	SARS	MERS	Seasonal Influenza	2019-nCoV [§]
Reproduction Ratio* (R_0)	2-5	0.3-0.8	1.3-1.8	1.4-3.8
Case Fatality Rate (CFR) (%) [†]	35	9	0.1	Outside Wuhan: 0.2 (Within Wuhan: 3.8)
Infectious Before Fever Onset if Symptomatic?	No	Yes	Yes	Yes
Total Number of Cases	200+	8,000+	5-20 million a year	100,000 and rising (of which 80,000 in China)

* Reproduction Ratio* (R_0) is the number of cases directly generated by one case in a population where all individuals are susceptible to infection and is a measure of infectivity.

[†] Case Fatality Rate (CFR) is the ratio of deaths from a disease to the total number of people diagnosed with this disease over a time period. It is conventionally expressed as a percentage and is a measure of disease severity.

[§] All values for COVID-19 are based on current data, are dynamic and hence, may vary by the end of COVID-19 pandemic. (Values for SARS, MERS and seasonal influenza are more stable because they are based on past outbreak data.)

i. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan ZQ, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang WY, Haque U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned. *Int J Epidemiol*. Published online on 22 Feb 2020 ahead of print. DOI: 10.1093/ije/dyaa033.

ii. CDC. Disease Burden of Influenza. Accessed <https://www.cdc.gov/flu/about/burden/index.html> on 17 Feb 2020.

iii. Zhang S, Diao M, Yu W, Pei L, Lin Z, Chen D, Estimation of the reproductive number of Novel Coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis, *International Journal of Infectious Diseases* (2020). doi: <https://doi.org/10.1016/j.ijid.2020.02.033>.

Table 2. WHO's major recommendations for countries with imported cases and/or outbreaks of 2019-nCoV

1. Activate the highest level of national Response Management protocols to ensure the all-of-government and all-of-society approach needed to contain COVID-19 with non-pharmaceutical public health measures.
2. Prioritize active, exhaustive case finding and immediate testing and isolation, painstaking contact tracing and rigorous quarantine of close contacts.
3. Fully educate the general public on the seriousness of COVID-19 and their role in preventing its spread.
4. Expand surveillance to detect COVID-19 transmission chains, by testing all patients with atypical pneumonias, conducting screening in some patients with upper respiratory illnesses and/or recent COVID-19 exposure, and adding testing for the COVID-19 virus to existing surveillance systems (e.g. systems for influenza-like-illness and severe acute respiratory infections).
5. Conduct multi-sector scenario planning and simulations for the deployment of even more stringent measures to interrupt transmission chains as needed (e.g. the suspension of large-scale gatherings and the closure of schools and workplaces).